Livforsakringsbolaget Skandia Omsesidigt Acquires 2,000 Shares of Bristol-Myers Squibb Co (NYSE:BMY)
Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 55,506 shares of the biopharmaceutical company’s stock after purchasing an additional 2,000 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Bristol-Myers Squibb were worth $2,518,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Financial Gravity Wealth Inc. bought a new position in shares of Bristol-Myers Squibb in the first quarter valued at approximately $26,000. Capital Financial Planning LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $28,000. Private Ocean LLC bought a new position in shares of Bristol-Myers Squibb in the first quarter valued at approximately $28,000. Well Done LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $30,000. Finally, Trust Department MB Financial Bank N A bought a new position in shares of Bristol-Myers Squibb in the first quarter valued at approximately $32,000. Hedge funds and other institutional investors own 77.60% of the company’s stock.
In other news, insider Karen Murphy Santiago sold 3,065 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the sale, the insider now owns 3,066 shares in the company, valued at approximately $145,818.96. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Theodore R. Samuels II bought 5,000 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were acquired at an average price of $47.29 per share, for a total transaction of $236,450.00. Following the acquisition, the director now owns 27,000 shares in the company, valued at approximately $1,276,830. The disclosure for this purchase can be found here. Insiders own 0.13% of the company’s stock.
Shares of NYSE BMY traded down $0.48 during mid-day trading on Tuesday, hitting $44.92. The stock had a trading volume of 4,252,757 shares, compared to its average volume of 13,183,990. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51. Bristol-Myers Squibb Co has a 1 year low of $42.48 and a 1 year high of $63.69. The business’s 50 day moving average price is $45.82. The stock has a market capitalization of $73.45 billion, a price-to-earnings ratio of 11.29, a P/E/G ratio of 2.07 and a beta of 0.71.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.12. The business had revenue of $6.27 billion for the quarter, compared to analysts’ expectations of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.01 earnings per share. On average, sell-side analysts predict that Bristol-Myers Squibb Co will post 4.26 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be issued a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.65%. The ex-dividend date is Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 41.21%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.